Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

                           ~financial statements to follow~

                                  PDL BIOPHARMA, INC.
                    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                       (in thousands, except per share amounts)
                                      (unaudited)

                                             Three Months Ended March 31,
                                            2009                      2008
    Revenues                              $62,622                   $50,205
    General and administrative expenses     4,693                    12,709
        Operating income                   57,929                    37,496
    Interest and other income, net            336                     4,864
    Interest expense                       (3,574)                   (3,555)
        Income from continuing
         operations before income
         taxes                             54,691                    38,805
    Income tax expense                     17,234                     1,034
        Income fr
'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... today announced that it will release its unaudited financial ... after market close on Wednesday, August 12, 2015. The Company ... 2015, at 8:00 a.m. EDT (Thursday, August 13, 2015 ... Company,s financial results and provide an update on recent ...
(Date:8/3/2015)... GREENVILLE, N.C. , Aug. 3, 2015 /PRNewswire/ ... will unveil its new Fingerprint Molecular Identification™ (FMID) ... Identification,s educational conference in Sacramento, Calif. ... in forensic science, will enable law enforcement agents, ... molecular profile of criminal suspects. By ...
(Date:8/3/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic and Dental sectors of healthcare, announced today that ... Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)... WESTWOOD, Mass. , Aug. 3, 2015  Merck ... company for innovative and top-quality high-tech products in the ... together with the US-based company Nano-C, their development and ... field of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... participate in the growing OPV sector. Novel ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4
... (Nasdaq: KNDL ) ("Kendle"), announced today that ... cash tender offer and consent solicitation for any and ... outstanding 3.375% Convertible Senior Notes due 2012 (CUSIP No. ... each $1,000.00 principal amount of Notes validly tendered and ...
... 2011 K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today ... divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the ... Inc. for approximately $60 million in cash. The transaction ... KV,s 2012 fiscal year, subject to customary closing conditions. ...
... for cell-based diagnostics and regenerative medicine therapies. However, being ... desired cell type -- such as muscle, skin, blood ... of these technologies. New research presented on June ... Society for Stem Cell Research (ISSCR) shows that systematically ...
Cached Biology Technology:Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 3Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 4K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 2K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 3K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 4K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 5K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 6K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 7Researchers engineer the environment for stem cell development to control differentiation 2Researchers engineer the environment for stem cell development to control differentiation 3
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Ont., June 21, 2011Researchers at St. Michael,s Hospital have found ... with kidney failure. Cells that help protect blood vessels ... the night than those who undergo standard daytime dialysis in ... This is important for patients with kidney failure, which ...
... Cervical ripening that instigates preterm labor is distinct ... labor, researchers at UT Southwestern Medical Center have found. ... cervical ripening and remodeling is likely just an accelerated ... term ripening is caused primarily by activation of inflammatory ...
... perception that bigger, stronger, faster organisms have a distinct ... in a given community. But new research from ... communities, organisms increase their chances of survival if they ... survive as well, a sort of "survival of the ...
Cached Biology News:New evidence of the benefits of home dialysis for kidney patients 2Researchers find process of cervical ripening differs between term and preterm birth 2Bacteria develop restraint for survival in a rock-paper-scissors community 2
... are well-characterized tissue-specific stem cells that exhibit ... the life-long maintenance of the hematopoietic system. ... adult bone marrow where hematopoiesis is continuously ... in cord blood, fetal liver, adult spleen ...
Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....
EDG-6 (1)...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: